2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, APL, MDS, MPN, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6362 Improved survival in FLT3 molecularly targeted therapy in acute myeloid leukemia: Real-world evidence from trinetx evaluation

Carina Hernandez, MD Phd, John Reagan, MD2
1 Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
2 Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States

Background

Acute myeloid leukemia (AML) is a biologically heterogeneous malignancy with variable responses to contemporary targeted therapies such as quizartinib (Erba et al. Lancet 2023) for FLT3-ITD (fms-like tyrosine kinase 3 with internal tandem duplication mutations) and midostaurin for both FLT3-ITD and FLT3-TKD (FLT3 with tyrosine kinase domain). With the introduction of molecularly targeted therapies the treatment landscape for AML has been transformed. Although randomized clinical trials have shown improved outcomes with these agents, real-world evidence evaluating their effectiveness remains limited. In this study we assessed overall survival associated with molecularly targeted therapy in a large real-world cohort focused on patients that were treated with FLT3 targeted therapies and those that were not. 

Methods

We performed a retrospective cohort study using the TriNetX Research Network. Adult patients with AML from 1/1/2020-7/1/2026 receiving first-line therapy were identified and divided into two independently analyzed cohorts. The primary analysis compared patients who received molecularly targeted therapy including FLT3 midostaurin, quizartinib, gilteritinib, with patients receiving non-targeted therapy. A separate subgroup analysis evaluated the patients with FLT3-ITD mutated only AML treated with quizartinib. The rationale was to determine whether the survival benefit observed in the broader targeted therapy cohort remained evident in a molecularly focused subgroup. Overall survival was defined as the time from initiation of AML therapy until death from any cause. 

A 1:1 propensity score matching analysis was done independently for the targeted groups and non-targeted groups using demographics, comorbidities, AML disease characteristics and baseline laboratory values as surrogates for patient fitness and leukemia burden. Kaplan-Meier curve was used to estimate overall survival and was compared using Cox proportional hazards models. 

Results

For the Primary FLT3-inhibitor cohort that included targeted therapies for both FLT3-ITD and FLT3-TKD, prior to matching the cohorts were 2,561 FLT3-targeted vs 20,786 non-targeted treatment. After propensity score matching, there were 2535 matched patients per cohort that showed treatment with FLT3 inhibitors was also associated with improved survival, with a median overall survival of 953 days compared with 718 days in patients receiving non-targeted therapy showing an improvement in survival by 235 days, Kaplan-Meier HR of 0.915 [95% CI 0.843-0.994], p =0.035. The adjusted Cox model had HR 0.924 [95% CI 0.867 -0.984), p=0.015 and the adjusted HR reduction was 7.6%. Survival benefit remained significant after adjustment.

Given that treatment exposure served as a surrogate for FLT3 mutation status, a sensitivity subgroup analysis was limited to quizartinib-treated patients because quizartinib is highly selective for FLT3-ITD, whereas midostaurin and gilteritinib inhibit both FLT3-ITD and FLT3-TKD. Prior to matching the cohorts were 248 vs 23,163 for the FLT3 targeted and non-targeted groups respectively. There were 246 propensity score-matched patients per cohort using demographics, comorbidities, AML characteristics and laboratory markers. The Median OS was not reached in the quizartinib cohort vs 869 days in the matched control cohort. The Kaplan-Meier curve did show a favorable trend toward improved survival with quizartinib with a 20% lower hazard of death, HR 0.80 [95% CI 0.58-1.10] however the difference did not reach statistical significance (log-rank p=0.17). Quizartinib was associated with 43% lower risk of death compared with the matched control cohort (25.3% vs 44.3%; RR 0.57,95% [CI 0.44-0.74], p=0.0001), likely due to the smaller matched cohort of 246 patients per group reducing the statistical power. The adjusted Cox model had HR 0.904 [95% CI 0.705-1.158] with a 9.6% relative hazard reduction but was not statistically significant p=0.4245.

Conclusions

In this real-world study, molecularly targeted FLT3 therapy was associated with improved overall survival among patients with AML and a statistically significant reduction in the hazard of death. Although the quizartinib subgroup did not reach statistical significance, the direction of effect remained consistent. Together these findings support potential survival benefit of FLT3 targeted therapy in FLT3-mutated AML and warrant validation in larger FLT3-ITD specific cohorts.

Carina Hernandez, MD Phd: No relevant conflicts of interest to declare.